datopotamab deruxtecan

Sponsor Astrazeneca PLC · listed as AZN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

datopotamab deruxtecan is a clinical-stage drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 3 forward catalysts for it — the nearest is a readout expected Sep 30, 2026 (day precision, medium confidence), tied to trial NCT06417814. The asset is in Phase 3 and currently recruiting, studied in Metastatic Non-small Cell Lung Cancer. It appears across 16 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2026-09-30

As disclosedSep 30, 2026

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06417814

PhasePHASE3

StatusRECRUITING

Lead sponsorAstraZeneca

Listed asAZN

Condition(s)Metastatic Non-small Cell Lung Cancer

All tracked catalysts for datopotamab deruxtecan

Date	Event	Confidence	Trial
2026-09-30	READOUT	medium	NCT06417814
2027-06-30	READOUT	medium	NCT06564844
2027-07-28	READOUT	medium	NCT06103864

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More AZN catalysts